Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Therapeutic Category
Cardiology, Cardiovascular, Hypertension/ Blood Pressure
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹175/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmeslide Trio 20 Tablet is a fixed-dose combination medication designed for the effective management of hypertension (high blood pressure). This formulation combines the therapeutic actions of three active ingredients:
The combination targets multiple pathways involved in hypertension, providing comprehensive blood pressure management and reducing the risk of complications like stroke, heart attack, and kidney damage. This tablet is particularly suitable for patients requiring multi-drug therapy for optimal blood pressure control.
Common side effects include dizziness, headache, fatigue, and mild swelling. Rarely, it may cause electrolyte imbalance or hypotension.
Indicated for the management of essential hypertension and reducing the risk of cardiovascular events.
Use only as directed by a healthcare professional. Regular monitoring of blood pressure and kidney function is recommended.
Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Cilnidipine (10 mg) + Olmesartan (20 mg) Tablet
Composition : Cilnidipine (10 mg) + Olmesartan (40 mg) + Chlorthalidone (12.5 mg) Tablet
Composition : Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Composition : Olmesartan Medoxomil (40 mg) + Chlorthalidone (12.5 mg) Tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan Medoxomil 20 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil + Cilnidipine + Chlorthalidone Tablet is a triple-combination antihypertensive therapy used for the management of high blood pressure (hypertension), particularly in patients who require multiple medications to achieve optimal blood pressure control. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that helps relax blood vessels. Cilnidipine is a calcium channel blocker that improves blood flow and reduces blood pressure. Chlorthalidone is a thiazide-like diuretic that helps remove excess fluid and sodium from the body. This combination provides comprehensive blood pressure management, making it a highly prescribed product in the cardiology and chronic care segment.
Medical distributors and wholesalers can benefit from strong and growing demand from cardiologists, physicians, and healthcare centers. Hypertension is one of the most prevalent chronic diseases worldwide, requiring long-term treatment and regular medication refills, resulting in consistent sales and repeat prescriptions.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in cardiology, chronic care, and general medicine segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic therapy adherence, increasing prevalence of hypertension, and strong specialist-driven demand, making it a stable, high-value, and repeat-prescription pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiology and chronic care products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the cardiovascular healthcare segment.